Fresenius Medical reports Q3 adjusted EPS EUR1.10 vs. EUR0.81 last year

Reports Q3 revenue EUR4.89B vs. EUR4.76B last year. “In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress. Our Group operating income margin of 11.7% extended well into the implied full year 2025 range of 11% to 12%. This demonstrates important progress on our trajectory to deliver our full year 2025 financial outlook”, said CEO Helen Giza. “All three operating segments contributed to the Group organic growth of 10%. U.S. same market treatment growth was slightly positive in Q3. Operating income in Care Enablement grew strongly by 38%, leading to a margin of 7.6%. In parallel, Care Delivery significantly improved profitability, reaching a strong margin of 14.5%, at the top end of its 2025 target margin band. We advanced our FME Reignite strategy for value creation with the launch of the first tranche of our initial share buyback program, the ownership increase in our Value-Based Care entity Interwell Health and the continued rollout of the 5008X in the U.S. For 2025, we are well on track to achieve our commitments, while we are excited about what lies ahead with FME Reignite.”